Literature DB >> 10706569

Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)

E L Murphy1, S M Bryzman, S A Glynn, D I Ameti, R A Thomson, A E Williams, C C Nass, H E Ownby, G B Schreiber, F Kong, K R Neal, G J Nemo.   

Abstract

Injection drug use (IDU) is a known risk factor for hepatitis C virus (HCV) infection, but the strength of other parenteral and sexual risk factors is unclear. In 1997, we performed a case-control study of 2,316 HCV-seropositive blood donors and 2,316 seronegative donors matched on age, sex, race/ethnicity, blood center, and first-time versus repeat-donor status. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Questionnaires were returned by 758 (33%) HCV(+) and 1,039 (45%) control subjects (P =.001). The final multivariate model included only the following independent HCV risk factors: IDU (OR = 49.6; 95% CI: 20.3-121.1), blood transfusion in non-IDU (OR = 10.9; 95% CI: 6.5-18.2), sex with an IDU (OR = 6.3; 95% CI: 3.3-12.0), having been in jail more than 3 days (OR = 2.9; 95% CI: 1.3-6.6), religious scarification (OR = 2.8; 95% CI: 1.2-7. 0), having been stuck or cut with a bloody object (OR = 2.1; 95% CI: 1.1-4.1), pierced ears or body parts (OR = 2.0; 95% CI: 1.1-3.7), and immunoglobulin injection (OR = 1.6; 95% CI: 1.0-2.6). Although drug inhalation and a high number of lifetime sex partners were significantly more common among HCV seropositives, they were not associated with HCV after controlling for IDU and other risk factors. IDU, blood transfusion among non-IDU, and sex with an IDU are strong risk factors for HCV among United States blood donors. Weaker associations with incarceration, religious scarification, being stuck or cut with a bloody object, pierced ears or body parts, and immunoglobulin injection must be interpreted with caution.

Entities:  

Mesh:

Year:  2000        PMID: 10706569     DOI: 10.1002/hep.510310329

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

1.  The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models.

Authors:  Yongshui Fu; Wenjie Xia; Yizhong Wang; Linwei Tian; Oliver G Pybus; Ling Lu; Kenrad Nelson
Journal:  Transfusion       Date:  2010-04-23       Impact factor: 3.157

2.  Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index.

Authors:  Edward L Murphy; Junyong Fang; Yongling Tu; Ritchard Cable; Christopher D Hillyer; Ronald Sacher; Darrell Triulzi; Jerome L Gottschall; Michael P Busch
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

3.  Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case-control study.

Authors:  Naser Ebrahimi Daryani; Mohsen Nassiri-Toosi; Armin Rashidi; Iman Khodarahmi
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

4.  Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France.

Authors:  C Brouard; P Pradat; E Delarocque-Astagneau; C Silvain
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

5.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

6.  Prevalence and correlates of Hepatitis C among injection drug users: The significance of duration of use, incarceration and race/ethnicity.

Authors:  William W Latimer; Sarra L Hedden; Leah Floyd; April Lawson; Alexander Melnikov; S Geoffrey Severtson; Anne-Gloria Moleko; Kristin Cole
Journal:  J Drug Issues       Date:  2009-09

7.  Treating chronic hepatitis C in recovering opiate addicts: yes, we can.

Authors:  M J Kreek; A H Talal; P Piccolo
Journal:  Dig Liver Dis       Date:  2009-02-23       Impact factor: 4.088

Review 8.  Transfusion transmission of HCV, a long but successful road map to safety.

Authors:  Suganya Selvarajah; Michael P Busch
Journal:  Antivir Ther       Date:  2012-12-07

9.  Risk factors for hepatitis C virus infection among blood donors in Georgia.

Authors:  Nickolas Zaller; Kenrad E Nelson; Malvina Aladashvili; Nino Badridze; Carlos del Rio; Tengiz Tsertsvadze
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

10.  Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Brian Custer; Jennie Orland; Angela Strollo; Sherri Cyrus; Michael P Busch; Edward L Murphy
Journal:  Am J Epidemiol       Date:  2008-01-17       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.